EarlyCDT-Lung diagnostic data

An international validation study in 3 cohorts of patients in the U.S. and Russia; Germany; and the U.S., U.K. and Ukraine, respectively, with newly diagnosed lung cancer (n=145, 241 and 269) showed that Oncimmune's EarlyCDT-Lung test had sensitivities of 36%, 39% and 37% and specificities of 91%, 89% and 90%, respectively. All patients in the first cohort were smokers. Additionally, there was no significant difference between different lung cancer stages detected by the test, which detected both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Furthermore, the presence of benign lung disease did not affect the specificity of the test. Data were published in Annals of Oncology. ...